TSI Investor Profile: ABcann

Company: ABcann


Country: Canada
Sector: Healthcare
Industry: Legal Cannabis
Established: 2012


Featured Video

Company Brief

Licensed since March 2014, ABcann sets itself apart from other Canadian licensed producers with its 94% customer retention rate, its focus on organic cultivation in proprietary growing chambers and its industry-leading  production yields in excess of 250 grams per sq. ft., double the industry average.

The company, which is in the process of developing its 65-acre site with a second 150K sq. ft. facility, has a research partnership with the University of Guelph and and has supplied innovative cannabis inhaler device maker Syqe Medical with its standardized cannabis.


Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity: 625 kilograms
Number of Patients: N/A
Headquarters: Napanee, Ontario

Financials (pro forma 09/30)

Cash on hand: $28.9mm
Fixed Investment: $5.72mm
Shareholders’ Equity: $17.8mm
Revenues – Last Quarter: N/A
Adj. Gross Margin: N/A

Capital Structure (04/23/17)

Last Financing: 12.875mm shares at $0.80
Basic Shares: 97.20mm
Warrants: 39.71mm
Options: 9.41mm
Diluted Shares: 173.83mm




  • Focus on pharmaceutical grade plant standardization
  • 94.7% customer retention rate
  • Organic production using exclusive, computer-controlled environmental system


Growth Strategy


  • Expand existing facility and construct 2nd facility targeting 40 kg/annum production capacity
  • Pursue global initiatives in Europe, Israel and Australia
  • Active discussions to license production to U.S. operators




  • Production through computer-controlled environmental systems
  • Industry-leading efficiency in terms of yield per square foot
  • Research partnership with University of Guelph

Exclusive Interview

Above Industry Average Yields

ABcann’s standardized organic growing methods yield not only a higher quality product as reflected by its premium pricing but also a lower overall cost. According to PI Financial, ABcann is able to produce almost double the industry average as measured by grams per square foot.


Strong Advisory Board Led by
the “Father of Cannabis Medicine”

Dr. Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.

ABcann to Acquire Leading B.C. Producer Canna Farms

ABcann Global Corporation (TSX-V:ABCN) (OTCQB:ABCCF) is pleased to announce that it has entered into a definitive agreement to acquire 100% of the issued and outstanding share capital of Canna Farms Limited, a premium cannabis company in British Columbia.

ABcann Launches Beacon Medical

ABcann Global Corporation (TSX-V:ABCN) is pleased to announce the launch of Beacon Medical, its new medical cannabis brand.

ABcann Global Corporation Announces $70 Million Bought Deal Financing

ABcann Global Corporation (TSXV:ABCN) announced today that it has entered into an agreement with Canaccord Genuity Corp. and Eight Capital, on their own behalf and on behalf of a syndicate of underwriters, pursuant to which the Underwriters will purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of: (i) 11,500,000 units of the Company at a price of $3.50 per Unit for aggregate gross proceeds of $40,250,000; and (ii) 30,000 unsecured convertible debentures of the Company at a price of $1,000 per Convertible Debenture for aggregate gross proceeds of $30,000,000.

ABcann Granted Australian Import License

ABCANN GLOBAL CORPORATION (TSXV: ABCN) is pleased to announce that its wholly-owned subsidiary, ABcann Australia Pty Ltd., has received an import license from the Federal Office of Drug Control in Australia.

ABcann Adds Big Alcohol Expertise with New Chief Marketing Officer

ABCANN GLOBAL CORPORATION (TSX-V:ABCN) is pleased to announce the appointment of Sung Kang as the Company's Chief Marketing Officer (CMO). Mr. Kang, who will assume the position effective January 8, 2018, was formerly the Head of Marketing for the Mike’s Beverage Company, Canada’s leading ready-to-drink and cider business, owned by Labatt Breweries of Canada.